In:
International Journal of Cancer, Wiley, Vol. 147, No. 2 ( 2020-07-15), p. 413-422
Abstract:
What's new? Endometrial cancers have the highest reported rate of PI3K pathway alterations of any solid tumor. A kinase inhibitor called MK‐2206, which blocks the PI3K pathway, has entered Phase II clinical trials. In this study, the authors predicted that tumors with PIK3CA mutations would be more susceptible to MK‐2206 than those without. However, this was not the case, and toxicity was also higher than expected. One group of patients did show clinical benefit: those whose tumors had serous histology. MK‐2206 is thus being further explored in these patients.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink